The Experts below are selected from a list of 551382 Experts worldwide ranked by ideXlab platform
Akihisa Imagawa - One of the best experts on this subject based on the ideXlab platform.
-
diagnostic criteria for acute onset Type 1 Diabetes mellitus 2012 report of the committee of japan Diabetes society on the research of fulminant and acute onset Type 1 Diabetes mellitus
Journal of Diabetes Investigation, 2014Co-Authors: Eiji Kawasaki, Akihisa Imagawa, Taro Maruyama, Takuya Awata, Hiroshi Ikegami, Yasuko Uchigata, Haruhiko Osawa, Yumiko Kawabata, Tetsuro Kobayashi, Akira ShimadaAbstract:Type 1 Diabetes is a disease characterized by destruction of pancreatic β-cells, which leads to absolute deficiency of insulin secretion. Depending on the manner of onset and progression, it is classified as fulminant, acute-onset or slowly progressive Type 1 Diabetes. Here, we propose the diagnostic criteria for acute-onset Type 1 Diabetes mellitus. Among the patients who develop ketosis or diabetic ketoacidosis within 3 months after the onset of hyperglycemic symptoms and require insulin treatment continuously after the diagnosis of Diabetes, those with anti-islet autoantibodies are diagnosed with ‘acute-onset Type 1 Diabetes mellitus (autoimmune)’. In contrast, those whose endogenous insulin secretion is exhausted (fasting serum C-peptide immunoreactivity <0.6 ng/mL) without verifiable anti-islet autoantibodies are diagnosed simply with ‘acute-onset Type 1 Diabetes mellitus’. Patients should be reevaluated after certain periods in case their statuses of anti-islet autoantibodies and/or endogenous insulin secretory capacity are unknown.
-
fulminant Type 1 Diabetes an important subType in east asia
Diabetes-metabolism Research and Reviews, 2011Co-Authors: Akihisa Imagawa, Toshiaki HanafusaAbstract:Fulminant Type 1 Diabetes is defined as a subType of Type 1 Diabetes with a remarkably acute onset. A nationwide survey identified that this variant accounts for approximately 20% of acute-onset Type 1 diabetic patients in Japan. Recent studies indicate that this is not a minor subType in other East Asian countries. As genetic factors, we revealed association of HLA-DR-DQ, HLA-B and CTLA-4 to fulminant Type 1 Diabetes. As an environmental factor, viral infection would contribute to the development of this subType. Cellular infiltration to islets was detected soon after the onset but not observed 1 month after the onset. Macrophages and T cells were the main components of the infiltrates. Enterovirus RNA and Toll-like receptor-3 expression, a signature of viral infection, was also observed. These findings suggest that viral infection in the susceptible individual might trigger anti-viral immune response and that pancreatic beta cells are rapidly destroyed through the accelerated immune reaction.
-
different contribution of class ii hla in fulminant and typical autoimmune Type 1 Diabetes mellitus
Diabetologia, 2005Co-Authors: Akihisa Imagawa, Toshiaki Hanafusa, Eiji Kawasaki, Taro Maruyama, Yasuko Uchigata, Tetsuro Kobayashi, Akira Shimada, Azuma Kanatsuka, Ikki Shimizu, Hideichi MakinoAbstract:Aims/hypothesis Fulminant Type 1 Diabetes, which is characterised by a markedly acute onset of Diabetes and an absence of islet-related autoantibodies, accounts for 20% of Type 1 Diabetes in Japan. We aimed to clarify the contribution of the HLA subType to fulminant Type 1 Diabetes in Japanese.
Akira Shimada - One of the best experts on this subject based on the ideXlab platform.
-
diagnostic criteria for acute onset Type 1 Diabetes mellitus 2012 report of the committee of japan Diabetes society on the research of fulminant and acute onset Type 1 Diabetes mellitus
Journal of Diabetes Investigation, 2014Co-Authors: Eiji Kawasaki, Akihisa Imagawa, Taro Maruyama, Takuya Awata, Hiroshi Ikegami, Yasuko Uchigata, Haruhiko Osawa, Yumiko Kawabata, Tetsuro Kobayashi, Akira ShimadaAbstract:Type 1 Diabetes is a disease characterized by destruction of pancreatic β-cells, which leads to absolute deficiency of insulin secretion. Depending on the manner of onset and progression, it is classified as fulminant, acute-onset or slowly progressive Type 1 Diabetes. Here, we propose the diagnostic criteria for acute-onset Type 1 Diabetes mellitus. Among the patients who develop ketosis or diabetic ketoacidosis within 3 months after the onset of hyperglycemic symptoms and require insulin treatment continuously after the diagnosis of Diabetes, those with anti-islet autoantibodies are diagnosed with ‘acute-onset Type 1 Diabetes mellitus (autoimmune)’. In contrast, those whose endogenous insulin secretion is exhausted (fasting serum C-peptide immunoreactivity <0.6 ng/mL) without verifiable anti-islet autoantibodies are diagnosed simply with ‘acute-onset Type 1 Diabetes mellitus’. Patients should be reevaluated after certain periods in case their statuses of anti-islet autoantibodies and/or endogenous insulin secretory capacity are unknown.
-
different contribution of class ii hla in fulminant and typical autoimmune Type 1 Diabetes mellitus
Diabetologia, 2005Co-Authors: Akihisa Imagawa, Toshiaki Hanafusa, Eiji Kawasaki, Taro Maruyama, Yasuko Uchigata, Tetsuro Kobayashi, Akira Shimada, Azuma Kanatsuka, Ikki Shimizu, Hideichi MakinoAbstract:Aims/hypothesis Fulminant Type 1 Diabetes, which is characterised by a markedly acute onset of Diabetes and an absence of islet-related autoantibodies, accounts for 20% of Type 1 Diabetes in Japan. We aimed to clarify the contribution of the HLA subType to fulminant Type 1 Diabetes in Japanese.
Eiji Kawasaki - One of the best experts on this subject based on the ideXlab platform.
-
diagnostic criteria for acute onset Type 1 Diabetes mellitus 2012 report of the committee of japan Diabetes society on the research of fulminant and acute onset Type 1 Diabetes mellitus
Journal of Diabetes Investigation, 2014Co-Authors: Eiji Kawasaki, Akihisa Imagawa, Taro Maruyama, Takuya Awata, Hiroshi Ikegami, Yasuko Uchigata, Haruhiko Osawa, Yumiko Kawabata, Tetsuro Kobayashi, Akira ShimadaAbstract:Type 1 Diabetes is a disease characterized by destruction of pancreatic β-cells, which leads to absolute deficiency of insulin secretion. Depending on the manner of onset and progression, it is classified as fulminant, acute-onset or slowly progressive Type 1 Diabetes. Here, we propose the diagnostic criteria for acute-onset Type 1 Diabetes mellitus. Among the patients who develop ketosis or diabetic ketoacidosis within 3 months after the onset of hyperglycemic symptoms and require insulin treatment continuously after the diagnosis of Diabetes, those with anti-islet autoantibodies are diagnosed with ‘acute-onset Type 1 Diabetes mellitus (autoimmune)’. In contrast, those whose endogenous insulin secretion is exhausted (fasting serum C-peptide immunoreactivity <0.6 ng/mL) without verifiable anti-islet autoantibodies are diagnosed simply with ‘acute-onset Type 1 Diabetes mellitus’. Patients should be reevaluated after certain periods in case their statuses of anti-islet autoantibodies and/or endogenous insulin secretory capacity are unknown.
-
different contribution of class ii hla in fulminant and typical autoimmune Type 1 Diabetes mellitus
Diabetologia, 2005Co-Authors: Akihisa Imagawa, Toshiaki Hanafusa, Eiji Kawasaki, Taro Maruyama, Yasuko Uchigata, Tetsuro Kobayashi, Akira Shimada, Azuma Kanatsuka, Ikki Shimizu, Hideichi MakinoAbstract:Aims/hypothesis Fulminant Type 1 Diabetes, which is characterised by a markedly acute onset of Diabetes and an absence of islet-related autoantibodies, accounts for 20% of Type 1 Diabetes in Japan. We aimed to clarify the contribution of the HLA subType to fulminant Type 1 Diabetes in Japanese.
Toshiaki Hanafusa - One of the best experts on this subject based on the ideXlab platform.
-
fulminant Type 1 Diabetes an important subType in east asia
Diabetes-metabolism Research and Reviews, 2011Co-Authors: Akihisa Imagawa, Toshiaki HanafusaAbstract:Fulminant Type 1 Diabetes is defined as a subType of Type 1 Diabetes with a remarkably acute onset. A nationwide survey identified that this variant accounts for approximately 20% of acute-onset Type 1 diabetic patients in Japan. Recent studies indicate that this is not a minor subType in other East Asian countries. As genetic factors, we revealed association of HLA-DR-DQ, HLA-B and CTLA-4 to fulminant Type 1 Diabetes. As an environmental factor, viral infection would contribute to the development of this subType. Cellular infiltration to islets was detected soon after the onset but not observed 1 month after the onset. Macrophages and T cells were the main components of the infiltrates. Enterovirus RNA and Toll-like receptor-3 expression, a signature of viral infection, was also observed. These findings suggest that viral infection in the susceptible individual might trigger anti-viral immune response and that pancreatic beta cells are rapidly destroyed through the accelerated immune reaction.
-
different contribution of class ii hla in fulminant and typical autoimmune Type 1 Diabetes mellitus
Diabetologia, 2005Co-Authors: Akihisa Imagawa, Toshiaki Hanafusa, Eiji Kawasaki, Taro Maruyama, Yasuko Uchigata, Tetsuro Kobayashi, Akira Shimada, Azuma Kanatsuka, Ikki Shimizu, Hideichi MakinoAbstract:Aims/hypothesis Fulminant Type 1 Diabetes, which is characterised by a markedly acute onset of Diabetes and an absence of islet-related autoantibodies, accounts for 20% of Type 1 Diabetes in Japan. We aimed to clarify the contribution of the HLA subType to fulminant Type 1 Diabetes in Japanese.
Antonino Mazzone - One of the best experts on this subject based on the ideXlab platform.
-
Teleconsultation in Type 1 Diabetes mellitus (TELEDIABE)
Acta Diabetologica, 2018Co-Authors: Federico Bertuzzi, Ilario Stefani, Benedetta Rivolta, Basilio Pintaudi, Elena Meneghini, Livio Luzi, Antonino MazzoneAbstract:Aims The growing incidence of Diabetes and the need to contain healthcare costs empower the necessity to identify new models of care. Telemedicine offers an acknowledged instrument to provide clinical health care at a distance, increasing patient compliance and the achievement of therapeutical goals. The objective was to test the feasibility and the efficacy in the improvement of the glycemic control of the teleconsultation for patients with Type 1 Diabetes mellitus. Methods A randomized open-label, parallel arms, controlled trial was conducted in two Diabetes centers in Italy. Participants affected by Type 1 Diabetes mellitus have been randomly (1:1) assigned to receive their visits as standard or a web-based care. Patients in the teleconsultation group can arrange their appointments on a Web site and can also have access to web educational courses or to nutritional and psychological counseling. The primary outcome was the assessment of glycemic control by HbA1c measurement after a 12-month follow-up. Results Overall 74 participants were followed for 1 year. HbA1c changes were not statistically different within ( p = 0.56 for standard care group; p = 0.45 for telemedicine group) and between ( p = 0.60) groups when considering differences from baseline to the end of the study. Patients randomized to teleconsultation reported reduced severe hypoglycemic episodes ( p = 0.03). In addition, they were largely satisfied with the activities, perceived a good improvement in the self-management of the Diabetes, and reported to have a time saving and a cost reduction. Conclusions In conclusion, TELEDIABE proposes a new system for the management of patients with Type 1 Diabetes mellitus.
-
teleconsultation in Type 1 Diabetes mellitus telediabe
Acta Diabetologica, 2018Co-Authors: Federico Bertuzzi, Ilario Stefani, Benedetta Rivolta, Basilio Pintaudi, Elena Meneghini, Livio Luzi, Antonino MazzoneAbstract:The growing incidence of Diabetes and the need to contain healthcare costs empower the necessity to identify new models of care. Telemedicine offers an acknowledged instrument to provide clinical health care at a distance, increasing patient compliance and the achievement of therapeutical goals. The objective was to test the feasibility and the efficacy in the improvement of the glycemic control of the teleconsultation for patients with Type 1 Diabetes mellitus. A randomized open-label, parallel arms, controlled trial was conducted in two Diabetes centers in Italy. Participants affected by Type 1 Diabetes mellitus have been randomly (1:1) assigned to receive their visits as standard or a web-based care. Patients in the teleconsultation group can arrange their appointments on a Web site and can also have access to web educational courses or to nutritional and psychological counseling. The primary outcome was the assessment of glycemic control by HbA1c measurement after a 12-month follow-up. Overall 74 participants were followed for 1 year. HbA1c changes were not statistically different within (p = 0.56 for standard care group; p = 0.45 for telemedicine group) and between (p = 0.60) groups when considering differences from baseline to the end of the study. Patients randomized to teleconsultation reported reduced severe hypoglycemic episodes (p = 0.03). In addition, they were largely satisfied with the activities, perceived a good improvement in the self-management of the Diabetes, and reported to have a time saving and a cost reduction. In conclusion, TELEDIABE proposes a new system for the management of patients with Type 1 Diabetes mellitus.
